Tvardi Therapeutics (NASDAQ:TVRD) Price Target Lowered to $4.00 at Barclays

Tvardi Therapeutics (NASDAQ:TVRD) had its price target lowered by equities research analysts at Barclays from $5.00 to $4.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price target points to a potential upside of 38.41% from the company’s previous close.

TVRD has been the subject of a number of other research reports. Wall Street Zen raised Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Finally, Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $46.00.

Tvardi Therapeutics Stock Down 9.1%

Shares of NASDAQ:TVRD traded down $0.29 during midday trading on Wednesday, reaching $2.89. The company’s stock had a trading volume of 98,692 shares, compared to its average volume of 63,048. The firm has a 50 day moving average of $3.81 and a 200-day moving average of $9.00. The firm has a market capitalization of $27.11 million, a P/E ratio of -0.30 and a beta of 0.14. Tvardi Therapeutics has a 12-month low of $2.81 and a 12-month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.23).

Institutional Investors Weigh In On Tvardi Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TVRD. Arax Advisory Partners increased its holdings in shares of Tvardi Therapeutics by 277.2% in the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after purchasing an additional 6,173 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Tvardi Therapeutics during the 2nd quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics in the 2nd quarter worth approximately $43,000. HRT Financial LP bought a new stake in Tvardi Therapeutics in the 4th quarter worth approximately $47,000. Finally, XTX Topco Ltd purchased a new stake in shares of Tvardi Therapeutics during the 4th quarter worth approximately $55,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.